Your Brazil CRO for local and international trials
Recent regulatory changes aim to reduce timelines in Brazil. This new legislation took into consideration the guidelines and processes from other international Regulatory Authorities, such as the FDA and EMA.
Carla Bertasso, Perpétua Rocha, Anderson Porto and Rodrigo Athanazio, Eurotrials Brazil
Brazil has one of the largest pharmaceutical markets in the world, and since 2001 Eurotrials has a strong local presence with the principal organizations and research centres. Positioning itself as a trustful local CRO with recognized quality, Eurotrials brings to this market the quality assurance and regulatory compliance necessary to guarantee the success of every clinical research project.
As the fifth most populous country in the world, Brazil has an unique heterogeneity in genetic profiles, which combined with highly concentrated population, low costs per patient and the quality of health services, makes the region an ideal place for conducting clinical trials in various therapeutic areas.
The low number of trials per capita foresees a wide range of high progression for the next decade, making the country an attractive market for our sector.
Eurotrials Brazil has more than 30 local professionals specially prepared for implementing, conducting and managing regional and international clinical trials projects.
Anderson Porto is Clinical Trials Country Director at Eurotrials, and is part of the team since 2008. Perpétua Rocha is Real World & Outcomes Research Country Director, also assuming the responsibilities of Clinical Data and T&T areas. Perpetua is at Eurotrials since 2006.
|Growth rate||0.8% (2014 est.)|
|Birth rate||14.72 births/1,000 population (2014 est.)|
|Death rate||6.54 deaths/1,000 population (2014 est.)|
|Life expectancy||73.28 years|
|Fertility rate||1.79 children born/woman (2014 est.)|
|Infant mortality rate||19.21 deaths/1,000 live births|
Al. Santos 787, cj31 – Cerqueira Cesar
01419-001 São Paulo, Brazil
Tel.: (5511) 3842 6888
Fax: (5511) 3842 6797